Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
ex vivo, lentiviral vector (lv)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (ids) enzyme to subjects with hunter syndrome
Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
ex vivo, lentiviral vector (lv)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (ids) enzyme to subjects with hunter syndrome